Patient's age and D-dimer levels predict the prognosis in patients with TAFRO syndrome.
Castleman disease
D-dimer
Prognosis
TAFRO syndrome
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
22
02
2021
accepted:
22
04
2021
revised:
22
04
2021
pubmed:
1
5
2021
medline:
10
8
2021
entrez:
30
4
2021
Statut:
ppublish
Résumé
To identify prognostic factors for TAFRO syndrome, a rare inflammatory disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly. Data of patients with TAFRO syndrome were extracted from a Japanese patient registry. Patients were divided into groups according to the clinical and laboratory parameters at initial presentation. Cut-off values for the laboratory parameters were determined using receiver operating characteristic curve analysis and by clinical relevance. Patient survival was analyzed by the Kaplan-Meier method. Univariable analysis was performed using log-rank tests. Multivariable analyses were performed with the logistic regression model and the Cox proportional hazards model. We extracted the data of 83 patients with TAFRO syndrome from the registry. Univariable analysis identified several potential prognostic factors. Of these factors, age ≥60 years and D-dimer ≥18 μg/dL remained significant predictors of poor overall survival in the multivariable Cox proportional hazards model. Based on these results, we developed a simple prognostic scoring system for TAFRO syndrome (TS-PSS). Patients in our cohort were stratified into low, intermediate, and high-risk groups by the TS-PSS. This system should be verified with independent patient cohorts in future studies.
Identifiants
pubmed: 33929719
doi: 10.1007/s12185-021-03159-x
pii: 10.1007/s12185-021-03159-x
pmc: PMC8085640
doi:
Substances chimiques
Biomarkers
0
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-188Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 17591060 and 15K09510
Organisme : Kanazawa Medical University
ID : S2004-16, S2007-5, K2011-7, H2011-11, AR2012-06
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. Japanese Society of Hematology.
Références
Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki. 2010;51:320–5.
pubmed: 20534952
Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al. Castleman-Kojima disease (TAFRO syndrome): A novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53:57–61.
doi: 10.3960/jslrt.53.57
Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129:1646–57.
doi: 10.1182/blood-2016-10-746933
Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135:1353–64.
doi: 10.1182/blood.2019000931
Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016;91:220–6.
doi: 10.1002/ajh.24242
Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975–83.
doi: 10.1002/ajh.25554
Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, et al. Atypical hyaline vascular-type Castleman’s disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop. 2013;53:87–93.
doi: 10.3960/jslrt.53.87
Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, et al. Successful treatment of a patient with multicentric Castleman’s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med. 2013;52:1503–7.
doi: 10.2169/internalmedicine.52.9482
Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, et al. Japanese variant of multicentric castleman’s disease associated with serositis and thrombocytopenia–a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop. 2013;53:79–85.
doi: 10.3960/jslrt.53.79
Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T, et al. The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman’s disease. BMC Pediatr. 2014;14:139.
doi: 10.1186/1471-2431-14-139
Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, et al. Successful treatment of TAFRO syndrome, a variant of multicentric Castleman’s disease, with cyclosporine A: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med. 2015;236:289–95.
doi: 10.1620/tjem.236.289
Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, et al. Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy—a case report. Exp Hematol Oncol. 2015;4:3.
doi: 10.1186/2162-3619-4-3
Fujiwara S, Mochinaga H, Nakata H, Ohshima K, Matsumoto M, Uchiba M, et al. Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. Int J Hematol. 2016;103:718–23.
doi: 10.1007/s12185-016-1978-2
Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019;129:4451–63.
doi: 10.1172/JCI126091
Miatech JL, Patel NR, Latuso NQ, Ellipeddi PK. TAFRO syndrome: a case of significant endocrinopathy in a Caucasian patient. Cureus. 2019;11:e4946.
pubmed: 31453020
pmcid: 6701897
van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132:2115–24.
doi: 10.1182/blood-2018-07-862334
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966–74.
doi: 10.1016/S1470-2045(14)70319-5
Fujimoto S, Kawabata H, Sakai T, Yanagisawa H, Nishikori M, Nara K, et al. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol. 2021;113:73–80.
doi: 10.1007/s12185-020-03008-3
Murakami M, Johkoh T, Hayashi S, Ohshima S, Mizuki M, Nakatsuka SI, et al. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan. Mod Rheumatol. 2020;30:843–51.
doi: 10.1080/14397595.2019.1704983
Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155–8.
doi: 10.1007/s12185-019-02780-1
Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96:644–7.
doi: 10.1111/j.1651-2227.2006.00178.x
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Mahajan P, Dass B, Radhakrishnan N, McCullough PA. COVID-19-associated systemic thromboembolism: a case report and review of the literature. Cardiorenal Med. 2020;10:462–9.
doi: 10.1159/000511800
Saito H, Tanaka K, Fujiwara M, Iwasaki T, Numata T, Oda A, et al. Pathological findings of progressive renal involvement in a patient with TAFRO syndrome. CEN Case Rep. 2019;8:239–45.
doi: 10.1007/s13730-019-00400-9
Nagayama Y, Yamano M, Yagame M, Nariyama T, Takahashi M, Kawamoto M, et al. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. BMC Nephrol. 2019;20:375.
doi: 10.1186/s12882-019-1574-9
Leurs A, Gnemmi V, Lionet A, Renaud L, Gibier JB, Copin MC, et al. Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review. Front Immunol. 2019;10:1489.
doi: 10.3389/fimmu.2019.01489
Ozeki T, Tsuji M, Yamamoto J, Shigematsu C, Maruyama S. Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome. CEN Case Rep. 2018;7:243–7.
doi: 10.1007/s13730-018-0338-x
Mizuno H, Sekine A, Oguro M, Oshima Y, Kawada M, Sumida K, et al. Renal histology in a patient with TAFRO syndrome: a case report. Hum Pathol. 2018;82:258–63.
doi: 10.1016/j.humpath.2018.03.021
Ganz T. Anemia of inflammation. N Engl J Med. 2019;381:1148–57.
doi: 10.1056/NEJMra1804281
Hall P, Cash J. What is the real function of the liver ‘function’ tests? Ulster Med J. 2012;81:30–6.
pubmed: 23536736
pmcid: 3609680
Masaki Y, Kawabata H, Fujimoto S, Kawano M, Iwaki N, Kotani T, et al. Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. J Clin Exp Hematop. 2019;59:175–8.
doi: 10.3960/jslrt.19021